Wilson Therapeutics Interim Report January 1-September 30, 2017

8.00 AM CET / 23-Nov-2017 / Wilson Therapeutics (STO:WTX) Ready for Phase 3 July 1 - September 30, 2017

  · Net sales amounted to SEK 0.0 M (0.0)

  · Loss for the period was SEK 29.4 M (loss: 31.9)

  · Loss per share, before and after dilution, totaled SEK 1.14 (loss: 1,24)

  · At September 30, cash and cash equivalents amounted to SEK 277.1 M (416.5)

January 1 - September 30, 2017

  · Net sales amounted to SEK 0.0 M (0.0)

  · Loss for the period was SEK 115.4 M (loss: 81.1)

  · Loss per share, before and after dilution, totaled SEK 4.49 (loss: 5.81)

Significant events during the period January 1 - September 30, 2017

  · Extraordinary general meeting was held in January 2017 and resolved to implement the long-term incentive program LTIP 2016

  · Data from the successfully completed Phase 2 trial were presented at major scientific conferences

  · Board strengthened by the appointments of Dr. Birgitte Volck and Dr. Björn Odlander

  · The AGM resolved to implement the long-term incentive program LTIP 2017

  · US Orphan Drug Designation granted for WTX101 for the treatment of ALS

Significant events after the end of the reporting period

  · Phase 2 data published in The Lancet Gastroenterology & Hepatology

  · Preliminary long-term data from the extension phase of the Phase 2 study presented at scientific conference

  · Agreement reached with the FDA and EMA to initiate pivotal Phase 3 FOCuS study

"We are excited to move WTX101 into the pivotal phase of development and initiate the first global, randomized, controlled, multi-center study ever conducted in Wilson Disease. The first patient is expected to be enrolled in the Phase 3 FOCuS study in early 2018."

Jonas Hansson, CEO of Wilson Therapeutics

Invitation to telephone conference

All interested parties are invited to participate in a web-cast telephone conference regarding the report today November 23 at 10:00 CET. The live webcast and a recorded on-demand version including the presentation material will be accessible at: https://tv.streamfabriken.com/wilson-therapeutics-q3-2017.

Questions can be asked in writing via the webcast or verbally via the conference call.

To participate in the conference call, please call one of the following numbers:

  · SE: +46 8 566 426 90

  · UK: +44 203 008 9801

  · US: +1 855 753 2235

The presentation material will also be published before the conference starts on Wilson Therapeutics' website www.wilsontherapeutics.com under Media & Investors/ Presentations. The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Wilson Therapeutics' website.

About Wilson Therapeutics

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders.

Wilson Therapeutics' lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Visit www.wilsontherapeutics.com for more information

For further information contact:

Jonas Hansson, CEO, Wilson Therapeutics AB

Telephone: +46 8 796 00 00

Email: jonas.hansson@wtx.se

Wilson Therapeutics AB (publ)

Corp. Reg. No. 556893-0357

Kungsgatan 3

SE-111 43 Stockholm